Article
Gag-Protease Sequence Evolution Following Protease Inhibitor Monotherapy Treatment Failure in HIV-1 Viruses Circulating in East Africa.
AIDS research and human retroviruses - 1 Oct 2015
Sutherland Katherine A, Goodall Ruth L, McCormick Adele, Kapaata Anne, Lyagoba Fred, Kaleebu Pontiano, Thiltgen Geant, Gilks Charles F, Spyer Moira, Kityo Cissy, Pillay Deenan, Dunn David, Gupta Ravindra K
Abstract excerpt
Around 2.5 million HIV-infected individuals failing first-line therapy qualify for boosted protease inhibitor (bPI)-based second-line therapy globally. Major resistance mutations are rarely present at treatment failure in patients receiving bPI and the determinants of failure in these patients remain unknown. There is evidence that Gag can impact PI susceptibility. Here, we have sequenced Gag-Protease before and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
